Drug Profile
Research programme: immuno-cancer therapeutics - Outlook Therapeutics
Alternative Names: ONS-1110Latest Information Update: 05 Dec 2018
Price :
$50
*
At a glance
- Originator Oncobiologics
- Developer Outlook Therapeutics
- Class Bispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 03 Dec 2018 Oncobiologics is now called Outlook Therapeutics
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 18 Oct 2011 Early research in Cancer in USA (Parenteral)